NRXP
NRx Pharmaceuticals, Inc.2.1000
+0.1200+6.06%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
62.17MP/E (TTM)
-Basic EPS (TTM)
-2.31Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
HOPE acquires Cohen clinic
NRx Pharmaceuticals' subsidiary HOPE Therapeutics completed its acquisition of a strategic minority interest in Cohen & Associates on October 17, 2025, integrating the Sarasota-based interventional psychiatry clinic into the HOPE Network. Dr. Rebecca Cohen, a TMS expert with over a decade of leadership, was appointed Medical Director to oversee Florida operations, with immediate expansion planned in Western Florida and Palm Beach. The move bolsters HOPE's offerings in ketamine and TMS for suicidal depression and PTSD. Acquisition expected to boost revenue and EBITDA.
8-K
FDA grants ketamine petition
NRx Pharmaceuticals scored FDA approval for its Suitability Petition on September 24, 2025, greenlighting the proposed strength of KETAFREE™, a single-patient, preservative-free ketamine that ditches toxic Benzethonium Chloride from multi-dose vials. This clears the path for immediate re-filing of the Abbreviated New Drug Application, targeting the $750 million ketamine market while aligning with U.S. policy pushes to reshore sterile drugs and purge harmful preservatives. FDA moves fast. The company eyes quick market entry, separate from its NRX-100 push for suicidal depression, though regulatory hurdles persist.
8-K
NRx completes Dura Medical acquisition
NRx Pharmaceuticals completed its acquisition of Dura Medical on September 8, 2025, integrating the Florida-based interventional psychiatry clinics in Naples and Ft. Myers into subsidiary HOPE Therapeutics. The deal, structured with cash, convertible membership interests, and performance-based earn-outs, adds revenue-generating, EBITDA-positive operations offering ketamine therapy and TMS for depression and PTSD, targeting veterans via VA partnerships. Stephen Durand steps in as Florida clinic operations director. This bolsters HOPE's network expansion amid rising suicide rates, though regulatory and integration risks persist.
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
LBRX
LB Pharmaceuticals Inc
19.82-0.04
NERV
Minerva Neurosciences, Inc
4.17+0.13
NLSP
NLS Pharmaceutics Ltd.
0.76+0.76
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60